Journal article
(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.
Abstract
To evaluate (18)F-labeled-fluorodeoxyglucose ((18)F-FDG-) and (18)F-labeled-sodium fluoride ((18)F-NaF-) positron emission tomography/computed tomography (PET/CT) as biomarkers in metastatic castrate-resistant prostate cancer (mCRPC). Nine men (53-75 years) in a phase 1 trial of abiraterone and cabozantinib had (18)F-FDG-PET/CT, (18)F-NaF-PET/CT and standard imaging ((99m)Tc-labeled-methylene-diphosphonate ((99m)Tc-MDP) bone scan and …
Authors
Zukotynski KA; Kim CK; Gerbaudo VH; Hainer J; Taplin M-E; Kantoff P; den Abbeele ADV; Seltzer S; Sweeney CJ
Journal
American Journal of Nuclear Medicine and Molecular Imaging, Vol. 5, No. 1, pp. 72–82
ISSN
2160-8407